UA76256C2 - Composition containing acid-unstable physiologically active compound and process for its preparation - Google Patents

Composition containing acid-unstable physiologically active compound and process for its preparation Download PDF

Info

Publication number: UA76256C2
Authority: UA; Ukraine
Prior art keywords: coating; composition; drug; water; enteric
Prior art date: 2001-11-21

Application number

UA20040604883A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-21

Filing date

2002-11-20

Publication date

2006-07-17

2002-11-20 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

2006-07-17 Publication of UA76256C2 publication Critical patent/UA76256C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 90
150000001875 compounds Chemical class 0.000 title claims abstract description 64
238000000034 method Methods 0.000 title claims description 32
238000002360 preparation method Methods 0.000 title abstract description 5
230000008569 process Effects 0.000 title description 3
229920000642 polymer Polymers 0.000 claims abstract description 44
229920003176 water-insoluble polymer Polymers 0.000 claims abstract description 39
238000000576 coating method Methods 0.000 claims description 98
239000011248 coating agent Substances 0.000 claims description 93
239000003814 drug Substances 0.000 claims description 52
229940079593 drug Drugs 0.000 claims description 51
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 34
239000000126 substance Substances 0.000 claims description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
-1 aminoalkyl methacrylate Chemical compound 0.000 claims description 18
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 18
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
229920001577 copolymer Polymers 0.000 claims description 12
229960004157 rabeprazole Drugs 0.000 claims description 12
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
239000004014 plasticizer Substances 0.000 claims description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
229960000541 cetyl alcohol Drugs 0.000 claims description 9
239000001856 Ethyl cellulose Substances 0.000 claims description 8
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
229920001249 ethyl cellulose Polymers 0.000 claims description 8
235000019325 ethyl cellulose Nutrition 0.000 claims description 8
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
159000000000 sodium salts Chemical group 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 5
235000019484 Rapeseed oil Nutrition 0.000 claims description 5
229920001800 Shellac Polymers 0.000 claims description 5
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 5
239000004359 castor oil Substances 0.000 claims description 5
235000019438 castor oil Nutrition 0.000 claims description 5
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
229920001223 polyethylene glycol Polymers 0.000 claims description 5
229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 5
239000004208 shellac Substances 0.000 claims description 5
229940113147 shellac Drugs 0.000 claims description 5
235000013874 shellac Nutrition 0.000 claims description 5
229920002545 silicone oil Polymers 0.000 claims description 5
229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
239000001069 triethyl citrate Substances 0.000 claims description 5
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 5
235000013769 triethyl citrate Nutrition 0.000 claims description 5
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims description 2
238000005507 spraying Methods 0.000 claims description 2
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
238000013268 sustained release Methods 0.000 abstract description 13
239000012730 sustained-release form Substances 0.000 abstract description 13
239000008280 blood Substances 0.000 abstract description 7
210000004369 blood Anatomy 0.000 abstract description 7
230000001225 therapeutic effect Effects 0.000 abstract description 5
238000004519 manufacturing process Methods 0.000 abstract description 4
238000003860 storage Methods 0.000 abstract description 2
239000003405 delayed action preparation Substances 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
239000000243 solution Substances 0.000 description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
238000009505 enteric coating Methods 0.000 description 18
239000002702 enteric coating Substances 0.000 description 18
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 17
229960000913 crospovidone Drugs 0.000 description 17
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 17
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 17
238000004090 dissolution Methods 0.000 description 16
230000003111 delayed effect Effects 0.000 description 14
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
239000010410 layer Substances 0.000 description 8
230000002378 acidificating effect Effects 0.000 description 7
239000000654 additive Substances 0.000 description 7
238000010828 elution Methods 0.000 description 7
239000002904 solvent Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000007884 disintegrant Substances 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
239000003086 colorant Substances 0.000 description 5
239000001863 hydroxypropyl cellulose Substances 0.000 description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
239000000454 talc Substances 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
239000004408 titanium dioxide Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
239000002245 particle Substances 0.000 description 4
229940045902 sodium stearyl fumarate Drugs 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
230000004584 weight gain Effects 0.000 description 4
235000019786 weight gain Nutrition 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
235000012730 carminic acid Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000027119 gastric acid secretion Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000004922 lacquer Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
229960000381 omeprazole Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
244000017106 Bixa orellana Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
235000012665 annatto Nutrition 0.000 description 2
239000010362 annatto Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000004106 carminic acid Substances 0.000 description 2
239000013068 control sample Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 2
229960003174 lansoprazole Drugs 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
229940117841 methacrylic acid copolymer Drugs 0.000 description 2
239000004531 microgranule Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
229960005019 pantoprazole Drugs 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
238000009495 sugar coating Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000012085 test solution Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
229940093475 2-ethoxyethanol Drugs 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
108010083204 Proton Pumps Proteins 0.000 description 1
235000014548 Rubus moluccanus Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
VEHZBMGMMPZMRJ-UHFFFAOYSA-N acetic acid;2-(diethylamino)acetic acid Chemical compound CC(O)=O.CCN(CC)CC(O)=O VEHZBMGMMPZMRJ-UHFFFAOYSA-N 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical group CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 description 1
229940114118 carminic acid Drugs 0.000 description 1
150000001746 carotenes Chemical class 0.000 description 1
235000005473 carotenes Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
229940080423 cochineal Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000576 food coloring agent Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
230000007774 longterm Effects 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
238000002156 mixing Methods 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000003672 processing method Methods 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940071138 stearyl fumarate Drugs 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA20040604883A 2001-11-21 2002-11-20 Composition containing acid-unstable physiologically active compound and process for its preparation UA76256C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001356018		2001-11-21
PCT/JP2002/012132 WO2003043661A1 (fr)	2001-11-21	2002-11-20	Compositions de preparation contenant des composes actifs au plan physiologiques et instables aux acides et leur procede de production

Publications (1)

Publication Number	Publication Date
UA76256C2 true UA76256C2 (en)	2006-07-17

Family

ID=19167613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040604883A UA76256C2 (en)	2001-11-21	2002-11-20	Composition containing acid-unstable physiologically active compound and process for its preparation

Country Status (25)

Country	Link
EP (1)	EP1454634A4 (is)
JP (1)	JP4540092B2 (is)
KR (1)	KR20050044545A (is)
CN (2)	CN101982199A (is)
AP (1)	AP1919A (is)
AU (1)	AU2002366029B2 (is)
BR (1)	BR0214372A (is)
CA (1)	CA2466726C (is)
CO (1)	CO5580800A2 (is)
CR (1)	CR7351A (is)
EC (1)	ECSP045110A (is)
HU (1)	HUP0402323A3 (is)
IL (2)	IL161983A0 (is)
IS (1)	IS7266A (is)
MA (1)	MA26346A1 (is)
MX (1)	MXPA04004775A (is)
NO (1)	NO20042563L (is)
NZ (1)	NZ532907A (is)
RO (1)	RO122395B1 (is)
RU (1)	RU2311906C2 (is)
SI (1)	SI21447A (is)
TW (1)	TWI302461B (is)
UA (1)	UA76256C2 (is)
WO (1)	WO2003043661A1 (is)
ZA (1)	ZA200403551B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20080095839A1 (en) *	2004-03-26	2008-04-24	Eisai R&D Management Co., Ltd.	Controlled-Release Pharmaceutical Composition and Method for Producing the Same
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
NZ728442A (en)	2004-10-21	2018-05-25	Adare Pharmaceuticals Inc	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
JP2008525313A (ja)	2004-12-27	2008-07-17	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬の安定化方法
CN101146521A (zh) *	2005-03-14	2008-03-19	太阳医药高级研究有限公司	提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
WO2006111853A2 (en) *	2005-04-18	2006-10-26	Aurobindo Pharma Limited	Stable solid dosage forms of acid labile drug
US9161918B2 (en) *	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
WO2008062320A2 (en) *	2006-10-06	2008-05-29	Eisai R&D Management Co., Ltd	Extended release formulations of a proton pump inhibitor
RU2414889C2 (ru) *	2007-11-16	2011-03-27	Общество С Ограниченной Ответственностью "Технология Лекарств"	Фармацевтическая композиция для лечения язвы желудка и двенадцатиперстной кишки в форме твердых желатиновых капсул, содержащая рабепразол или его производные, и способ ее получения
CN101878041A (zh) *	2007-11-27	2010-11-03	大原药品工业株式会社	颗粒制剂的制造方法
CN101822671A (zh) *	2009-03-06	2010-09-08	信谊药厂	雷贝拉唑组合物及其制备方法
AU2010325746B2 (en)	2009-12-02	2016-02-25	Adare Pharmaceuticals S.R.L.	Fexofenadine microcapsules and compositions containing them
NZ605562A (en) *	2010-07-09	2013-11-29	Teijin Pharma Ltd	Deuterated benzylbenzene derivatives and methods of use
JP2018184360A (ja) *	2017-04-25	2018-11-22	ニプロ株式会社	経口投与用の腸溶性徐放性製剤
KR102227486B1 (ko) *	2017-06-30	2021-03-12	롯데정밀화학 주식회사	프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2336218C3 (de) *	1973-07-17	1985-11-14	Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz	Orale Arzneiform
JPS5944311A (ja) *	1982-09-07	1984-03-12	Santen Pharmaceut Co Ltd	徐放性顆粒およびその製造法
ES2077023T3 (es) *	1989-03-10	1995-11-16	Yamanouchi Pharma Co Ltd	Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
GB8926639D0 (en) *	1989-11-24	1990-01-17	Agricultural & Food Res	Delayed release formulations
EP0447168A3 (en) *	1990-03-16	1993-01-07	Yamanouchi Pharmaceutical Co. Ltd.	Long acting granular pharmaceutical composition
JPH0826977A (ja) *	1994-07-19	1996-01-30	Tanabe Seiyaku Co Ltd	溶出制御型経口製剤
JPH09323926A (ja) *	1996-03-15	1997-12-16	Nikken Chem Co Ltd	バルプロ酸ナトリウムの徐放性錠剤
ES2137862B1 (es) *	1997-07-31	2000-09-16	Intexim S A	Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
CA2298823C (en) *	1998-04-20	2011-06-07	Eisai Co., Ltd.	Stabilized composition comprising a benzimidazole type compound
DK2263660T3 (en) *	1998-05-18	2018-01-02	Takeda Pharmaceuticals Co	Orally disintegrating tablets.
JP2001055322A (ja) *	1999-08-18	2001-02-27	Tanabe Seiyaku Co Ltd	パルス放出型製剤
MXPA02003762A (es) *	1999-10-20	2002-09-30	Eisai Co Ltd	Metodos para estabilizar compuestos basados en benzimidazol.
US6627223B2 (en) *	2000-02-11	2003-09-30	Eurand Pharmaceuticals Ltd.	Timed pulsatile drug delivery systems

2002
- 2002-11-20 CA CA2466726A patent/CA2466726C/en not_active Expired - Fee Related
- 2002-11-20 NZ NZ532907A patent/NZ532907A/en not_active IP Right Cessation
- 2002-11-20 WO PCT/JP2002/012132 patent/WO2003043661A1/ja not_active Ceased
- 2002-11-20 JP JP2003545339A patent/JP4540092B2/ja not_active Expired - Fee Related
- 2002-11-20 RU RU2004118495/15A patent/RU2311906C2/ru not_active IP Right Cessation
- 2002-11-20 EP EP02803548A patent/EP1454634A4/en not_active Withdrawn
- 2002-11-20 HU HU0402323A patent/HUP0402323A3/hu unknown
- 2002-11-20 IL IL16198302A patent/IL161983A0/xx unknown
- 2002-11-20 AU AU2002366029A patent/AU2002366029B2/en not_active Ceased
- 2002-11-20 BR BR0214372-0A patent/BR0214372A/pt not_active IP Right Cessation
- 2002-11-20 CN CN2010105157913A patent/CN101982199A/zh active Pending
- 2002-11-20 CN CNA02823233XA patent/CN1589156A/zh active Pending
- 2002-11-20 AP APAP/P/2004/003045A patent/AP1919A/en active
- 2002-11-20 UA UA20040604883A patent/UA76256C2/uk unknown
- 2002-11-20 RO ROA200400455A patent/RO122395B1/ro unknown
- 2002-11-20 SI SI200220036A patent/SI21447A/sl not_active IP Right Cessation
- 2002-11-20 MX MXPA04004775A patent/MXPA04004775A/es active IP Right Grant
- 2002-11-20 KR KR1020047007672A patent/KR20050044545A/ko not_active Ceased
- 2002-11-21 TW TW091133989A patent/TWI302461B/zh not_active IP Right Cessation
2004
- 2004-05-10 ZA ZA200403551A patent/ZA200403551B/en unknown
- 2004-05-13 IL IL161983A patent/IL161983A/en active IP Right Review Request
- 2004-05-14 IS IS7266A patent/IS7266A/is unknown
- 2004-05-17 EC EC2004005110A patent/ECSP045110A/es unknown
- 2004-05-18 MA MA27683A patent/MA26346A1/fr unknown
- 2004-05-18 CO CO04045751A patent/CO5580800A2/es not_active Application Discontinuation
- 2004-05-20 CR CR7351A patent/CR7351A/es unknown
- 2004-06-18 NO NO20042563A patent/NO20042563L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MA26346A1 (fr)	2004-10-01
CN101982199A (zh)	2011-03-02
TW200300353A (en)	2003-06-01
AU2002366029B2 (en)	2008-01-31
CN1589156A (zh)	2005-03-02
RU2311906C2 (ru)	2007-12-10
CR7351A (es)	2005-05-12
AP1919A (en)	2008-11-13
IS7266A (is)	2004-05-14
CA2466726C (en)	2011-02-22
JP4540092B2 (ja)	2010-09-08
MXPA04004775A (es)	2005-02-17
RO122395B1 (ro)	2009-05-29
BR0214372A (pt)	2004-10-26
EP1454634A4 (en)	2007-05-30
HUP0402323A3 (en)	2008-04-28
TWI302461B (en)	2008-11-01
IL161983A0 (en)	2005-11-20
SI21447A (sl)	2004-10-31
AP2004003045A0 (en)	2004-06-30
CA2466726A1 (en)	2003-05-30
NO20042563L (no)	2004-06-18
NZ532907A (en)	2007-05-31
RU2004118495A (ru)	2005-03-20
AU2002366029A1 (en)	2003-06-10
CO5580800A2 (es)	2005-11-30
ECSP045110A (es)	2004-08-27
HUP0402323A2 (hu)	2005-02-28
IL161983A (en)	2009-11-18
JPWO2003043661A1 (ja)	2005-03-10
ZA200403551B (en)	2005-07-07
WO2003043661A1 (fr)	2003-05-30
EP1454634A1 (en)	2004-09-08
KR20050044545A (ko)	2005-05-12

Publication	Publication Date	Title
DE69832621T2 (de)	2006-07-27	Neue pharmazeutische formulierungen mit kontrollierter freigabe von wirkstoffen
KR910004579B1 (ko)	1991-07-06	오메프라졸 경구 제형의 제조 방법
US6066339A (en)	2000-05-23	Oral morphine multiparticulate formulation
UA76256C2 (en)	2006-07-17	Composition containing acid-unstable physiologically active compound and process for its preparation
CA2109697C (en)	2005-11-22	Oral-administration forms of a medicament containing pantoprazole
FI119141B (fi)	2008-08-15	Menetelmä farmaseuttisen formulaation valmistamiseksi
KR100794078B1 (ko)	2008-01-10	용출 제어 제제 및 그의 제조 방법
EP1213015B1 (en)	2006-05-03	Oral pharmaceutical composition with delayed release of proton pump inhibitors
CA2724533C (en)	2014-07-29	Stabilized atypical antipsychotic formulation
BG64967B1 (bg)	2006-11-30	Метод за получаване на орален фармацевтичен препарат, включващ съединение с противоязвена активност
CA2342209A1 (en)	2000-03-09	Omeprazole formulation
RU2259828C2 (ru)	2005-09-10	Способы стабилизации соединений на основе бензимидазола
KR20010040502A (ko)	2001-05-15	위보호성 오메프라졸 마이크로그래뉼, 이것의 제조방법 및약학적 제제
EP0378137A2 (de)	1990-07-18	Neue Arzneiform
WO2005027876A1 (en)	2005-03-31	Pharmaceutical compositions of benzimidazole and processes for their preparation
RU2605388C2 (ru)	2016-12-20	Пероральный твердый препарат комбинированного противотуберкулезного лекарственного средства и способ его получения
US20050163846A1 (en)	2005-07-28	Preparation composition containing acid-unstable physiologically active compound, and process for producing same
CA2517289A1 (en)	2004-09-10	Stable pharmaceutical composition of rabeprazole and processes for their preparation
HK1068271A (en)	2005-04-29	Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
CA2558783C (en)	2013-01-22	Oral morphine multiparticulate formulation
CA2392353A1 (en)	2001-05-31	Stable acid labile benzimidazole pharmaceutical compositions